How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

629 results for

D-Penicillamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. D-Penicillamine for preventing retinopathy of prematurity in preterm infants. (Abstract)

D-Penicillamine for preventing retinopathy of prematurity in preterm infants. The rate of retinopathy of prematurity (ROP) in moderately premature infants has decreased dramatically with improved care in the neonatal intensive care unit. A low rate of this disorder was unexpectedly observed among infants treated with intravenous D-penicillamine to prevent hyperbilirubinaemia. This observation led to the investigation of its use, both enterally as well as intravenously, to prevent ROP.To (...) determine the effect of prophylactic administration of D-penicillamine on the incidence of acute ROP or severe ROP and other morbidities in preterm infants.We used the Cochrane Neonatal Review Group search strategy. Two review authors independently searched multiple electronic databases, previous reviews including cross references, abstracts, conference/symposia proceedings, and expert informants. We updated the search on November 27, 2012.We included randomised or quasi-randomised controlled trials

2013 Cochrane

2. Trolovol (D-penicillamine) - Disease-modifying treatment of rheumatoid arthritis, Treatment of Wilson's disease

Trolovol (D-penicillamine) - Disease-modifying treatment of rheumatoid arthritis, Treatment of Wilson's disease HAS - Medical, Economic and Public Health Assessment Division 1/7 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 23 July 2014 TROLOVOL 300 mg, film-coated tablet B/30 (CIP: 34009 320 316 9 6) Applicant: IMAXO INN D-penicillamine ATC Code (2012) M01CC01 (Specific antirheumatic agents) Reason (...) not identify clinical data with acceptable methodology published since the Committee's last opinion to assess the efficacy of D-penicillamine in the treatment of rheumatoid arthritis. Its structural efficacy in rheumatoid arthritis has not been demonstrated. 4.1.2 Wilson's disease The company provided three publications 1,2,3 on the efficacy of penicillamine for this indication. A literature review included studies published before January 2008, concerning the effectiveness of copper chelating agents

2015 Haute Autorite de sante

3. Urinary Abnormalities in Children and Adolescents with Wilson Disease Before and During Treatment with D-Penicillamine. (Abstract)

Urinary Abnormalities in Children and Adolescents with Wilson Disease Before and During Treatment with D-Penicillamine. Renal abnormalities can occur at any time point during the course of Wilson disease (WD). We aimed to fill a literature gap in this respect by studying urinary abnormalities in children and adolescents with WD.This study included 60 children with WD presenting to the Pediatric Hepatology Unit, Cairo University. The following data were retrieved from patients' files including (...) respectively.Asymptomatic urinary abnormalities are present in patients with WD at any time point of the disease and during treatment with d-penicillamine. They have to be searched for, as early intervention may prevent progression to renal insufficiency.This article is protected by copyright. All rights reserved.

2019 Journal of gastroenterology and hepatology

4. Synthesis and Characterization of Controlled Nitric Oxide Release from S-Nitroso-N-Acetyl-d-Penicillamine Covalently Linked to Polyvinyl Chloride (SNAP-PVC) Full Text available with Trip Pro

Synthesis and Characterization of Controlled Nitric Oxide Release from S-Nitroso-N-Acetyl-d-Penicillamine Covalently Linked to Polyvinyl Chloride (SNAP-PVC) Polyvinyl chloride (PVC) is one of the most widely used polymers in medicine but has very poor biocompatibility when in contact with tissue or blood. To increase biocompatibility, controlled release of nitric oxide (NO) can be utilized to mitigate and reduce the inflammatory response. A synthetic route is described where PVC is aminated (...) to a specified degree and then further modified by covalently linking S-nitroso-N-acetyl-d-penicillamine (SNAP) groups to the free primary amine sites to create a nitric oxide releasing polymer (SNAP-PVC). Controllable release of NO from SNAP-PVC is described using photoinitiation from light emitting diodes (LEDs). Ion-mediated NO release is also demonstrated as another pathway to provide a passive mechanism for NO delivery. The large range of NO fluxes obtained from the SNAP-PVC films indicate many

2018 Bioengineering

5. Chemosensitivity of U251 Cells to the Co-treatment of D-Penicillamine and Copper: Possible Implications on Wilson Disease Patients Full Text available with Trip Pro

Chemosensitivity of U251 Cells to the Co-treatment of D-Penicillamine and Copper: Possible Implications on Wilson Disease Patients D-Penicillamine (PA), a copper chelator, and one of the recommended drugs for treatment of Wilson disease (WD) has been reported to worsen the symptoms of patients with neurologic presentations. However, the cause of this paradoxical response has not been fully elucidated and requires further investigations. Accordingly, we have studied the in vitro effect of Copper

2017 Frontiers in molecular neuroscience

6. Pre-Clinical Studies with D-Penicillamine as a Novel Pharmacological Strategy to Treat Alcoholism: Updated Evidences Full Text available with Trip Pro

Pre-Clinical Studies with D-Penicillamine as a Novel Pharmacological Strategy to Treat Alcoholism: Updated Evidences Ethanol, as other drugs of abuse, is able to activate the ventral tegmental area dopamine (VTA-DA) neurons leading to positively motivational alcohol-seeking behavior and use, and, ultimately to ethanol addiction. In the last decades, the involvement of brain-derived acetaldehyde (ACD) in the ethanol actions in the mesolimbic pathway has been widely demonstrated. Consistent (...) published results have provided a mechanistic support to the use of ACD inactivating agents to block the motivational and reinforcing properties of ethanol. Hence, in the last years, several pre-clinical studies have been performed in order to analyze the effects of the sequestering ACD agents in the prevention of ethanol relapse-like drinking behavior as well as in chronic alcohol consumption. In this sense, one of the most explored interventions has been the administration of D-Penicillamine (DP

2017 Frontiers in behavioral neuroscience

7. Intracerebroventricular administration of the (1→6)-β-d-glucan (lasiodiplodan) in male rats prevents d-penicillamine-induced behavioral alterations and lipoperoxidation in the cortex Full Text available with Trip Pro

Intracerebroventricular administration of the (1→6)-β-d-glucan (lasiodiplodan) in male rats prevents d-penicillamine-induced behavioral alterations and lipoperoxidation in the cortex Lasiodiplodan, an exocellular (1→6)-β-d-glucan of molecular weight >1.4 × 106 Da produced by MMPI strain of Lasiodiplodia theobromae (Pat.) Griffon & Maubl. (Brotyosphaeriaceae) is known to exhibit anti-proliferative activity on breast cancer cells (MCF-7), anticoagulant activity when sulfonylated, and reduction (...) in transaminase activity when administered in rats.The effect of intracerebroventricular (I.C.V) injection of lasiodiplodan on neurotoxicity and behavioural changes induced by d-penicillamine was investigated.Twenty-four male Wistar rats were initially separated in groups of six and treated with 0.15 μmol/μL of NaCl (Groups Ct and d-Pen) and 0.01 μg/μL of lasiodiplodan (Groups Las and Las + d-Pen). After 15 min, they received 6 μmol/μL of NaCl (Groups Ct and Las) and 2 μmol/μL of d-penicillamine (Groups d-Pen

2017 Pharmaceutical biology

8. D-penicillamine-induced Elastosis Perforans Serpiginosa Full Text available with Trip Pro

D-penicillamine-induced Elastosis Perforans Serpiginosa 28776563 2018 10 09 2018 11 13 2542-5641 130 16 2017 Aug 20 Chinese medical journal Chin. Med. J. D-penicillamine-induced Elastosis Perforans Serpiginosa. 2013-2014 10.4103/0366-6999.211899 Yao Xue-Yan XY Department of Dermatology, Peking University People's Hospital, Beijing 100044, China. Wen Guang-Dong GD Department of Dermatology, Peking University People's Hospital, Beijing 100044, China. Zhou Cheng C Department of Dermatology, Peking

2017 Chinese medical journal

9. D-penicillamine combined with inhibitors of hydroperoxide metabolism enhances lung and breast cancer cell responses to radiation and carboplatin via H2O2-mediated oxidative stress Full Text available with Trip Pro

D-penicillamine combined with inhibitors of hydroperoxide metabolism enhances lung and breast cancer cell responses to radiation and carboplatin via H2O2-mediated oxidative stress D-penicillamine (DPEN), a copper chelator, has been used in the treatment of Wilson's disease, cystinuria, and rheumatoid arthritis. Recent evidence suggests that DPEN in combination with biologically relevant copper (Cu) concentrations generates H2O2 in cancer cell cultures, but the effects of this on cancer cell

2017 Free radical biology & medicine

10. D-Penicillamine

D-Penicillamine D-Penicillamine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 D-Penicillamine D-Penicillamine Aka: D-Penicillamine (...) Lowest Effective Dose: 500 mg per day VII. Dosing: Wilson's Disease Penicillamine 1 g PO before meals and at bedtime Keep Serum free copper <2 umol/L (<10 ug/dl) Continue life-long in VIII. Monitoring (2-3 times weekly on starting Penicillamine) IX. Precautions Observe for Treat hypersensitivity with if occurs Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "D-Penicillamine." Click on the image (or right click) to open the source

2018 FP Notebook

11. Measurement of urinary copper excretion after 48-h d-penicillamine cessation as a compliance assessment in Wilson’s disease Full Text available with Trip Pro

Measurement of urinary copper excretion after 48-h d-penicillamine cessation as a compliance assessment in Wilson’s disease Treatment of Wilson's disease (WD) with anti-copper agents is effective in most compliant patients. During long-term treatment with chelating agents, a two-day interruption of the treatment should result in normal urinary copper concentrations (<50 μg/dl). The aim of this study was to establish the usefulness of this method as a compliance assessment in these patients (...) . We examined consecutive patients treated with d-penicillamine (DPA) undergoing routine follow-up studies at our center. We performed 24-h urinary copper excretion analysis 48 h after interruption of chelating therapy. Thirty-two patients were enrolled. After DPA cessation, normalization of copper excretion was observed in 91% of reportedly compliant patients. The specificity and sensitivity values of this test were 87% and 77%, respectively. Measurement of 24-h urinary copper excretion after a 48

2016 Functional Neurology

12. Clinical efficacy of combined sodium dimercaptopropanesulfonate and zinc treatment in neurological Wilson’s disease with D-penicillamine treatment failure Full Text available with Trip Pro

Clinical efficacy of combined sodium dimercaptopropanesulfonate and zinc treatment in neurological Wilson’s disease with D-penicillamine treatment failure There are limited pharmacological treatments for patients with neurological Wilson's disease (WD) and a history of copper-chelating treatment failure.We retrospectively evaluated the clinical records of 38 patients with WD who were treated with sodium dimercaptopropanesulfonate (DMPS) and zinc (group 1) or zinc alone (group 2). All patients (...) had a history of neurological deterioration during their previous treatment with D-penicillamine (DPA).Twenty-one patients were treated with intravenous DMPS for 4 weeks, followed by zinc gluconate for 6 months, and the treatment protocol was repeated twice. Relative to the baseline, repeated DMPS therapy and zinc maintenance therapy decreased neurological scores continuously (p < 0.01). Sixteen patients (76.2%) demonstrated neurological improvements after 1 year of therapy and four patients (19.0

2016 Therapeutic advances in neurological disorders

13. Functional analysis and drug response to zinc and D-penicillamine in stable ATP7B mutant hepatic cell lines Full Text available with Trip Pro

Functional analysis and drug response to zinc and D-penicillamine in stable ATP7B mutant hepatic cell lines To study the effect of anti-copper treatment for survival of hepatic cells expressing different ATP7B mutations in cell culture.The most common Wilson disease (WD) mutations p.H1069Q, p.R778L and p.C271*, found in the ATP7B gene encoding a liver copper transporter, were studied. The mutations represent major genotypes of the United States and Europe, China, and India, respectively (...) of mutant p.H1069Q and to a lesser extent p.C271* improved by D-penicillamine (DPA) treatment, while mutant p.R778L showed a pronounced response to zinc (Zn) treatment. Overall, DPA treatment resulted in higher cell survival as compared to Zn treatment; however, only combined Zn + DPA treatment fully restored cell viability.The data indicate that the basic impact of a genotype might be characterized by analysis of mutant hepatic cell lines.

2016 World Journal of Gastroenterology

14. Protective Effects of D-Penicillamine on Catecholamine-Induced Myocardial Injury Full Text available with Trip Pro

Protective Effects of D-Penicillamine on Catecholamine-Induced Myocardial Injury Iron and copper release participates in the myocardial injury under ischemic conditions and hence protection might be achieved by iron chelators. Data on copper chelation are, however, sparse. The effect of the clinically used copper chelator D-penicillamine in the catecholamine model of acute myocardial injury was tested in cardiomyoblast cell line H9c2 and in Wistar Han rats. D-Penicillamine had a protective (...) effect against catecholamine-induced injury both in vitro and in vivo. It protected H9c2 cells against the catecholamine-induced viability loss in a dose-dependent manner. In animals, both intravenous D-penicillamine doses of 11 (low) and 44 mg/kg (high) decreased the mortality caused by s.c. isoprenaline (100 mg/kg) from 36% to 14% and 22%, respectively. However, whereas the low D-penicillamine dose decreased the release of cardiac troponin T (specific marker of myocardial injury), the high dose

2015 Oxidative medicine and cellular longevity

15. A Novel Method for the Synthesis of 99mTc-Ofloxacin Kits Using D-Penicillamine as Coligand and Their Application as Infection Imaging Agent Full Text available with Trip Pro

A Novel Method for the Synthesis of 99mTc-Ofloxacin Kits Using D-Penicillamine as Coligand and Their Application as Infection Imaging Agent The employment of radiopharmaceuticals is increasing nowadays for infection imaging and early execution of patients having infectious or inflammatory complaints. The main aim of this study was to discover a novel method for the labeling of ofloxacin with (99m)Tc, optimization of labelling conditions to get higher percent yield, to assess kits radiochemical (...) purity, in vitro stability, partition coefficient, protein binding, and intracellular accumulation in Pseudomonas aeruginosa, Salmonella typhi, and Escherichia coli in infected rabbits. Maximum labeling efficiency was achieved when 1.5 mg ofloxacin was labeled with 10-20 mCi sodium pertechnetate in the presence of 3 mg D-penicillamine, 75 μg SnCl₂. In vitro binding and biodistribution in Pseudomonas aeruginosa, Salmonella typhi, and Escherichia coli showed good results. This new complex is efficient

2015 BioMed research international

16. A controlled trial of D-penicillamine therapy in primary biliary cirrhosis. (Abstract)

A controlled trial of D-penicillamine therapy in primary biliary cirrhosis. D-penicillamine, 900 mg daily, was used in a randomised controlled trial for treatment of patients with primary biliary cirrhosis. 19 patients received D-penicillamine and 13 received placebo. The two groups were similar in age, duration of illness, liver function tests, and liver histology. Before entry into the trial liver-copper concentration was raised in 25 of the 27 patients in whom it was measured. After three (...) months patients taking D-penicillamine showed a significant reduction in serum-aspartate-transaminase concentrations compared with the placebo group, and this reduction seemed to be sustained. In the 4 patients on D-penicillamine for a year, a second liver biopsy showed that mean liver-copper concentration fell from 310 +/- 128 (S.E.M.) to 84 +/- 36 microng/g dry liver, compared with a reduction from 511 +/- 169 to 454 +/- 128 in the 7 patients in the placebo group in whom serial liver-copper

1977 Lancet Controlled trial quality: uncertain

17. Reduction of immune complexes and immunoglobulins induced by D-penicillamine in primary biliary cirrhosis. (Abstract)

Reduction of immune complexes and immunoglobulins induced by D-penicillamine in primary biliary cirrhosis. Penicillamine has an effect on immune complexes and immunoglobulins both in vivo and in vitro. We therefore studied the effect of penicillamine on immune complexes and immunoglobulins in primary biliary cirrhosis. Twenty-eight patients were randomly allocated into a treatment group receiving 600 to 900 mg of penicillamine, or a control group, and followed for a maximum of 24 months. After

1979 NEJM Controlled trial quality: uncertain

18. Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine

Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02426905 Recruitment Status : Active

2014 Clinical Trials

19. D-penicillamine-induced membranous nephropathy Full Text available with Trip Pro

D-penicillamine-induced membranous nephropathy 25120302 2014 08 14 2018 11 13 0971-4065 24 3 2014 May Indian journal of nephrology Indian J Nephrol D-penicillamine-induced membranous nephropathy. 195-6 10.4103/0971-4065.132024 Kumar R P Senthil RP Department of Nephrology, Stanley Medical College, Chennai, Tamil Nadu, India. Prasad N D Srinivasa ND Department of Nephrology, Stanley Medical College, Chennai, Tamil Nadu, India. Tirumavalavan S S Department of Nephrology, Stanley Medical College

2014 Indian Journal of Nephrology

20. Addition of D-penicillamine, hypotaurine, and epinephrine (PHE) mixture to IVF medium maintains motility and longevity of bovine sperm and enhances stable production of blastocysts in vitro Full Text available with Trip Pro

Addition of D-penicillamine, hypotaurine, and epinephrine (PHE) mixture to IVF medium maintains motility and longevity of bovine sperm and enhances stable production of blastocysts in vitro The present study aimed to establish an efficient system for bovine embryo production by in vitro fertilization (IVF) that can achieve stable normal fertilization and blastocyst developmental rates in any bull without optimization of the sperm concentration in IVF medium. We examined the effects of a PHE (...) mixture (20 μM D-penicillamine, 10 μM hypotaurine and 1 μM epinephrine), theophylline (2.5 mM), and sperm concentration (1, 2 or 5 × 10(6) cells/ml) on fertilization and blastocyst developmental rates. High cleavage rates (78.3 to 92.4%) and blastocyst developmental rates (31.9 to 62.0%) at day 7 were obtained in the presence of PHE and theophylline in IVF medium with a sperm concentration of 2 × 10(6) cells/ml using sperm from 9 bulls. In addition, the synergistic effect of PHE and theophylline

2014 The Journal of reproduction and development

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>